Subscribe To

Price Alert Latest News Economic Calendar News

KYMR / Kymera Therapeutics - Need More Developments Before Making This A Buy

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug Designation for KT-253, a potential treatment for acute myeloid leukemia, boosting its prospects. KYMR's partnership with Sanofi provides significant funding opportunities, but the company's lack of profitability and potential need for capital raises are concerning. Read More

Demo Live Account See Partner Details

Content Topics

Kymera

Therapeutics

Need

Developments

Before

Making

Stock

KYMR

Posted: Aug 9 2023, 16:21

Author Name: Seeking Alpha

KYMR News

By Seeking Alpha
November 4, 2023

Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript

Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q3 2023 Earnings Call Transcript November 2, 2023 8:00 AM ET Company Participants Justine Koenigsberg - VP, I

By Zacks Investment Research
October 19, 2023

Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Kymera Therapeutics, Inc. (KYMR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong

By Zacks Investment Research
October 18, 2023

Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Kymera Therapeutics, Inc. (KYMR) as it is technically in oversold territory now. In addition to th

By Zacks Investment Research
October 4, 2023

Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?

Kymera Therapeutics, Inc. (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings

By The Motley Fool
October 3, 2023

Why Shares of Kymera Therapeutics Jumped on Tuesday

Kymera Therapeutics has nine programs in its pipeline. It has a collaboration with Sanofi on its lead therapy IRAK-4.

By Seeking Alpha
August 9, 2023

Kymera Therapeutics - Need More Developments Before Making This A Buy

Kymera Therapeutics' valuation is difficult to estimate due to lack of positive net income, making it a poor buy. The company received FDA Orphan Drug

By Seeking Alpha
August 6, 2023

Perella Weinberg Partners (PWP) Q2 2023 Earnings Call Transcript

Perella Weinberg Partners (PWP) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Bruce Jacobs - CFO Nello Mainolfi - Fo

By Seeking Alpha
May 14, 2023

Kymera: More Data Needed

Kymera produced solid-looking phase 1 data, but Pfizer's problems in the space, along with some safety issues, hurt its stock. When partner Sanofi pro

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.